🎗️ Проект автоматически собирает и публикует онкологические новости из проверенных медицинских источников — 24/7, со ссылкой на первоисточник
Английские новости переводятся автоматически

🎗️Лента новостей

Онкология

‘Complexities’ stymie biosimilar cost savings despite FDA action

The question of whether a biosimilar is as comparably effective as its originator has largely been put to rest by clinical trials, real-world experience and a recent FDA guidance. However, this has not made biosimilars more accessible or affordable. “As with all things in the prescription drug space, there are a lot…